By Dan Radovsky | More Articles | Save For Later
July 29, 2013 | Comments (0)
Pfizer (NYSE: PFE ) plans to internally separate its commercial operations into three separate business segments, the company announced today. Two of those segments will include what the company calls innovative business lines, and a third will include its value lines.
One of the innovative segments will include products that cover several therapeutic areas, including inflammation and immunology, CV/metabolic, neuroscience and pain, rare diseases, and women's and men's health. Those products will have market exclusivity beyond 2015